Longevity of the novel ConvaTec infusion set with Lantern technology

被引:18
作者
Lal, Rayhan A. [1 ,2 ,3 ]
Hsu, Liana [1 ]
Zhang, Jian [2 ]
Schondorff, Pernelle K. [4 ]
Heschel, Matthias [4 ]
Buckingham, Bruce [1 ,3 ]
机构
[1] Stanford Univ, Dept Pediat, Div Endocrinol, Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Div Endocrinol, Sch Med, Stanford, CA 94305 USA
[3] Stanford Diabet Res Ctr, Stanford, CA USA
[4] ConvaTec, Copenhagen, Denmark
关键词
CSII; insulin pump therapy; insulin therapy; type; 1; diabetes;
D O I
10.1111/dom.14395
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current insulin infusion sets are approved for only 2-3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty-five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets (P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set.
引用
收藏
页码:1973 / 1977
页数:5
相关论文
共 14 条
[1]  
[Anonymous], 2016, WHY DO SOM PEOPL T1D
[2]   Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes [J].
Bode, BW ;
Strange, P .
DIABETES CARE, 2001, 24 (01) :69-72
[3]   A Head-to-Head Comparison Study of the First-Day Performance of Two Factory-Calibrated CGM Systems [J].
Denham, Douglas .
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (02) :493-495
[4]  
Heinemann Lutz, 2012, J Diabetes Sci Technol, V6, P954
[5]   Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes [J].
Karlin, Andrew W. ;
Ly, Trang T. ;
Pyle, Laura ;
Forlenza, Gregory P. ;
Messer, Laurel ;
Wadwa, R. Paul ;
DeSalvo, Daniel J. ;
Payne, Sydney L. ;
Hanes, Sarah ;
Clinton, Paula ;
Maahs, David M. ;
Buckingham, Bruce .
DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (07) :429-435
[6]  
Norgaard Kirsten, 2015, J Diabetes Sci Technol, V9, P215, DOI 10.1177/1932296814567326
[7]   Randomized Trial of Infusion Set Function: Steel Versus Teflon [J].
Patel, Parul J. ;
Benasi, Kari ;
Ferrari, Gina ;
Evans, Mark G. ;
Shanmugham, Satya ;
Wilson, Darrell M. ;
Buckingham, Bruce A. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (01) :15-19
[8]   First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus [J].
Rumpler, M. ;
Mader, J. K. ;
Fischer, J. P. ;
Thar, R. ;
Granger, J. M. ;
Deliane, F. ;
Klimant, I. ;
Aberer, F. ;
Sinner, F. ;
Pieber, T. R. ;
Hajnsek, M. .
BIOSENSORS & BIOELECTRONICS, 2017, 88 :240-248
[9]  
Schmid Volkmar, 2010, J Diabetes Sci Technol, V4, P976
[10]   Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion [J].
Thethi, Tina K. ;
Rao, Ajay ;
Kawji, Haytham ;
Mallik, Tilak ;
Yau, C. Lillian ;
Christians, Uwe ;
Fonseca, Vivian .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2010, 24 (02) :73-78